특허 및 논문

바이오솔빅스에 자료실을 확인해 보세요.
bt_bb_section_bottom_section_coverage_image

BIOSOLVIX ARCHIVE특허 및 논문

Antiviral activity and safety of remdesivir against SARS-CoV- 2 infection in human pluripotent stem cell-derived cardiomyocytes

작성자
관리자
작성일
2024-02-01 21:34
조회
249

Choi SW*, Shin JS*, Park SJ*, Jung EH, Park YG, Lee JH, Kim SJ, Park HJ, Lee JH,Park SM, Moon SH*, Ban KW*, Go YY*. Antiviral activity and safety of remdesivir against SARS-CoV- 2 infection in human pluripotent stem cell-derived cardiomyocytes. Antiviral Research. 2020 Dec;184:104955.


Abstract


Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is considered as the most significant global public health crisis of the century. Several drug candidates have been suggested as potential therapeutic options for COVID-19, including remdesivir, currently the only authorized drug for use under an Emergency Use Authorization. However, there is only limited information regarding the safety profiles of the proposed drugs, in particular drug-induced cardiotoxicity. Here, we evaluated the antiviral activity and cardiotoxicity of remdesivir using cardiomyocytes-derived from human pluripotent stem cells (hPSC-CMs) as an alternative source of human primary cardiomyocytes (CMs). In this study, remdesivir exhibited up to 60-fold higher antiviral activity in hPSC-CMs compared to Vero E6 cells; however, it also induced moderate cardiotoxicity in these cells. To gain further insight into the drug-induced arrhythmogenic risk, we assessed QT interval prolongation and automaticity of remdesivir-treated hPSC-CMs using a multielectrode array (MEA). As a result, the data indicated a potential risk of QT prolongation when remdesivir is used at concentrations higher than the estimated peak plasma concentration. Therefore, we conclude that close monitoring of the electrocardiographic/QT interval should be advised in SARS-CoV-2-infected patients under remdesivir medication, in particular individuals with pre-existing heart conditions.



Keywords

#COVID-19 #SARS-CoV-2  #Human cardiomyocytes #Pluripotent stem cells #Remdesivir

논문확인(클릭시 이동)
전체 52
번호 제목 작성자 작성일 추천 조회
42
Multiple isogenic GNE-myopathy modeling with mutation specific phenotypes from human pluripotent stem cells by base editors.
관리자 | 2024.02.02 | 추천 0 | 조회 232
관리자 2024.02.02 0 232
41
In silico design and fabrication of an SFI chip-based microspheroid culture system.
관리자 | 2024.02.02 | 추천 0 | 조회 290
관리자 2024.02.02 0 290
40
Effect and application of cryopreserved three-dimensional microcardiac spheroids in myocardial infarction therapy
관리자 | 2024.02.01 | 추천 0 | 조회 231
관리자 2024.02.01 0 231
39
Blue laser-induced selective vasorelaxation by the activation of NOSs.
관리자 | 2024.02.01 | 추천 0 | 조회 241
관리자 2024.02.01 0 241
38
Therapeutic Efficacy of Artificial Skin Produced by 3D Bioprinting.
관리자 | 2024.02.01 | 추천 0 | 조회 267
관리자 2024.02.01 0 267
37
Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization  international pharmacov
관리자 | 2024.02.01 | 추천 0 | 조회 238
관리자 2024.02.01 0 238
36
Predicting in vivo therapeutic efficacy of bioorthogonally labeled endothelial progenitor cells in hind limb ischemia models vi
관리자 | 2024.02.01 | 추천 0 | 조회 228
관리자 2024.02.01 0 228
35
Application of co-culture technology of epithelial type cells and mesenchymal type cells using nanopatterned structures
관리자 | 2024.02.01 | 추천 0 | 조회 264
관리자 2024.02.01 0 264
34
Development of genetic quality tests for good manufacturing practice-compliant induced pluripotent stem cells and their derivat
관리자 | 2024.02.01 | 추천 0 | 조회 288
관리자 2024.02.01 0 288
33
Antiviral activity and safety of remdesivir against SARS-CoV- 2 infection in human pluripotent stem cell-derived cardiomyocytes
관리자 | 2024.02.01 | 추천 0 | 조회 249
관리자 2024.02.01 0 249